VSL#3 – the first highly concentrated therapeutic probiotic with multiple bacterial strains and a proven therapeutic efficacy

Česká verzia

Authors: Luděk Hrdlička
Authors place of work: IBD centrum, Chirurgické oddělení, NH Hospital a. s., Nemocnice Hořovice ; Gastroenterologie, Poliklinika Budějovická, Medicon, a. s., Praha
Published in the journal: Gastroent Hepatol 2018; 72(1): 85-86
Category: Lékový profil
doi: https://doi.org/10.14735/amgh201885

Zdroje

1. Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7 (11): 1202–1209. doi: 10.1016/j.cgh.2009.07.016.

2. Miele E, Pascarella F, Giannetti E et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009; 104 (2): 437–443. doi: 10.1038/ajg.2008.118.

3. Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind randomized placebo-controlled study. Am J Gastroenterol 2010; 105 (10): 2218–2227. doi: 10.1038/ajg.2010.218.

4. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365 (18): 1713–1725. doi: 10.1056/NEJMra1102942.

5. Gionchetti P, Rizzllo F, Venturi A et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124 (5): 1202–1209.

6. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108–114.

7. Kim HJ, Vazquez Roque MI, Camilleri M et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17 (5): 687–696.

8. Wong RK, Yang C, Song GH et al. Melatonin regulation as a possible mechanizm for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci 2015; 60 (1): 186–194. doi: 10.1007/s10620-014-3299-8.

9. Kim HJ, Camilleri M, McKinzie S et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17 (7): 895–904.

10. Parkes GC, Chatoor D, Emmanuel A. The probiotic VSL#3 increases scbm and reduces symptom severity scores in patients with functional constipation. Gut 2011; 60 (Suppl 1) : A163. doi: 10.1136/gut.2011.239301.345.